← Back

Calidi Biotherapeutics Inc.

Calidi Biotherapeutics, Inc. is a biotechnology company that develops targeted therapies to deliver genetic medicines to distal sites of disease. Its pipeline includes CLD-101, which is in a Phase 1b/2 clinical trial for newly diagnosed high-grade glioma and a Phase 1 dose-escalation trial for recurrent high-grade glioma; CLD-201 for solid tumors such as breast cancer, head and neck cancer, and sarcoma; and CLD-401 for metastatic solid tumors. The company also offers oncolytic virus platforms, including NeuroNova and SuperNova. Founded in 2014, Calidi Biotherapeutics is headquartered in San Diego, California.

Country
Price · split & dividend adjusted
News & notes moving CLDI
CLDI▼2

Calidi Biotherapeutics announces 1-for-16 reverse stock split, shares drop 15% premarket

Calidi Biotherapeutics announced a 1-for-16 reverse stock split of its outstanding common stock, effective July 31, 2026, sending shares down 15.03% in premarket trading to $0.0978. The split, approved by shareholders on June 12 and the board on July 15, will convert every 16 pre-split shares into one post-split share, with fractional shares rounded up. The company stated the move aims to optimize market dynamics, broaden investor appeal, and align trading conditions with shareholder interests. Proportionate adjustments will be made to outstanding stock options, warrants, convertible securities, and equity incentive plans, while the par value and number of authorized shares remain unchanged. The stock will trade on a split-adjusted basis on the NYSE American under the ticker CLDI, with a new CUSIP number 320703507.
CLDI ▼
RTTNews·59dRead more →
CLDI

Calidi Biotherapeutics grants inducement stock option to new VP Finance

Calidi Biotherapeutics has granted an inducement non-qualified stock option to newly appointed VP Finance, Controller Sandra Gurrola for the purchase of 100,000 shares at an exercise price of $0.15, the closing price on the July 6, 2026 grant date. The option vests over four years, with 25% vesting on the one-year anniversary and the remainder in equal monthly installments through July 6, 2030. The grant was approved by the Compensation Committee and Board of Directors as a material inducement to Ms. Gurrola’s employment under Section 711 of the NYSE American LLC Company Guide.
CLDI
GlobeNewswire·72dRead more →
CLDI▲2

Calidi Biotherapeutics Appoints Former Celgene Executive Corsee Sanders to Board

Calidi Biotherapeutics has appointed Corsee Sanders as an independent director on its Board of Directors, effective June 17, 2026. Sanders previously served as Senior Vice President, Global Head of Clinical Operations at Genentech/Roche Holdings for six years, and as Executive Vice President of Development Operations at Juno, later becoming a strategic advisor to the Chief Medical Officer after Celgene acquired Juno. She also acted as Transition Advisor to Bristol Myers Squibb following its acquisition by Celgene, helping integrate Juno's CAR-T cell development organization. Sanders currently holds board seats at Legend Biotech Corporation, Ultragenyx Pharmaceutical Inc., and AltruBio Inc. Calidi shares closed Tuesday at $0.1560, down 2.50%, and were trading down 1.92% to $0.1530 in the pre-market.
CLDI ▲
RTTNews·86dRead more →
© 2026 MarketDXAsset